Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and effectiveness of giroctocogene fitelparvovec and fidanacogene elaparvovec in hemophilia A and B
2025-523660-21-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Therapies
- Countries
- 15
01
Overview
Phase 3, open-label trial of giroctocogene fitelparvovec and fidanacogene elaparvovec in hemophilia A and hemophilia B (HB) (2 cohorts), sponsored by Pfizer. Primary endpoints: Incidence of thromboembolic events, Incidence of factor inhibitor development and 3 more. Planned start Jul 2026; status: authorised.
02
Drugs
giroctocogene fitelparvovecfidanacogene elaparvovec
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2025-523660-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523660-21-00.